Trials / Completed
CompletedNCT00994123
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
A Phase 1-2 Trial of MM-121 in Combination With Erlotinib in Three Groups of Patients With Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 162 (actual)
- Sponsor
- Merrimack Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 1-2 study of MM-121 in combination with standard therapy for non-small cell lung cancer (NSCLC).
Detailed description
Phase 1: Patients with Non-Small Cell Lung Cancer (NSCLC) may be enrolled to evaluate the safety, tolerability and recommended Phase 2 dose of MM-121 in combination with standard therapy. Phase 2: Patients with Non-Small Cell Lung Cancer (NSCLC) may be enrolled to estimate the progression-free survival of the MM-121 + standard therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MM-121 | MM-121 (SAR256212) = intravenous solution |
| DRUG | Erlotinib | erlotinib = daily oral tablet |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2014-11-01
- Completion
- 2015-06-01
- First posted
- 2009-10-14
- Last updated
- 2016-08-22
- Results posted
- 2016-08-22
Locations
38 sites across 6 countries: United States, Canada, Germany, South Korea, Spain, Taiwan
Source: ClinicalTrials.gov record NCT00994123. Inclusion in this directory is not an endorsement.